Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rallybio (RLYB)
NASDAQ:RLYB
Holding RLYB?
Track your performance easily
RLYB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.95 - $3.46
Previous Close$0.99
Volume64.92K
Average Volume (3M)70.26K
Market Cap
$41.13M
Enterprise Value-$47.20M
Total Cash (Recent Filing)$88.61M
Total Debt (Recent Filing)$284.00K
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Mar 18, 2025EPS Estimate
-$0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.59
Shares Outstanding41,487,586
10 Day Avg. Volume71,708
30 Day Avg. Volume70,256
Standard Deviation0.29
R-Squared0.08
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)0.51
Price to Sales (P/S)140.14
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-157.84
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.61
Forecast
1Y Price Target
$6.50Price Target Upside555.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Rallybio News
PremiumCompany Announcements
Dr. Kush Parmar Steps Down from Rallybio’s Board and Committee
Bulls Say, Bears Say
Bulls Say
Clinical TrialsRallybio received approval from the EMA and MHRA to proceed with a Phase 2 trial of RLYB212, a significant step forward for their research.
Financial PerformanceRallybio reported a net loss per share lower than the prior estimate, indicating better-than-expected financial performance.
Potential Market OpportunityRLYB212 could potentially become the standard treatment for FNAIT, as there is currently no FDA-approved therapy available.
Bears Say
Analyst RecommendationAnalyst's recommendation includes lowering the 12-month target to $5 from the prior $6 per share after making operating expense adjustments.
EarningsRLYB reported a net loss of $11.5 million in the third quarter.
Financial PerformanceRallybio recorded a net loss of $0.26 per share.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RLYB FAQ
What was Rallybio’s price range in the past 12 months?
Rallybio lowest stock price was $0.95 and its highest was $3.46 in the past 12 months.
What is Rallybio’s market cap?
Currently, no data Available
When is Rallybio’s upcoming earnings report date?
Rallybio’s upcoming earnings report date is Mar 18, 2025 which is in 115 days.
How were Rallybio’s earnings last quarter?
Rallybio released its earnings results on Nov 07, 2024. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.352 by $0.092.
Is Rallybio overvalued?
According to Wall Street analysts Rallybio’s price is currently Undervalued.
Does Rallybio pay dividends?
Rallybio does not currently pay dividends.
What is Rallybio’s EPS estimate?
Rallybio’s EPS estimate is -$0.29.
How many shares outstanding does Rallybio have?
Rallybio has 41,487,587 shares outstanding.
What happened to Rallybio’s price movement after its last earnings report?
Rallybio reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.352. Following the earnings report the stock price went down -1%.
Which hedge fund is a major shareholder of Rallybio?
Among the largest hedge funds holding Rallybio’s share is Viking Global Investors LP. It holds Rallybio’s shares valued at 6M.
---
Rallybio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.50 (555.57% Upside)
$6.50 (555.57% Upside)
Blogger Sentiment
Bearish
RLYB Sentiment 100%
Sector Average 73%
Sector Average 73%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.0%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.55%
12-Months-Change
Fundamentals
Return on Equity
-68.90%
Trailing 12-Months
Asset Growth
-40.68%
Trailing 12-Months
Company Description
Rallybio
Rallybio Corp is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its lead program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
---
RLYB Stock 12 Month Forecast
Average Price Target
$6.50
▲(555.57% Upside)
Technical Analysis
Best Analysts Covering RLYB
1 Year
1 Year Success Rate
3/16 ratings generated profit
1 Year Average Return
-43.17%
reiterated a buy rating 15 days ago
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 18.75% of your transactions generating a profit, with an average return of -43.17% per trade.
---